178 related articles for article (PubMed ID: 15654351)
1. Use of natural killer cells in hematopoetic stem cell transplantation.
Passweg JR; Stern M; Koehl U; Uharek L; Tichelli A
Bone Marrow Transplant; 2005 Apr; 35(7):637-43. PubMed ID: 15654351
[TBL] [Abstract][Full Text] [Related]
2. Natural-killer-cell-based treatment in haematopoietic stem-cell transplantation.
Passweg JR; Koehl U; Uharek L; Meyer-Monard S; Tichelli A
Best Pract Res Clin Haematol; 2006; 19(4):811-24. PubMed ID: 16997185
[TBL] [Abstract][Full Text] [Related]
3. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
[TBL] [Abstract][Full Text] [Related]
4. Clinical-grade purification of natural killer cells in haploidentical hematopoietic stem cell transplantation.
Meyer-Monard S; Passweg J; Siegler U; Kalberer C; Koehl U; Rovó A; Halter J; Stern M; Heim D; Alois Gratwohl JR; Tichelli A
Transfusion; 2009 Feb; 49(2):362-71. PubMed ID: 19389215
[TBL] [Abstract][Full Text] [Related]
5. Reconstitution of natural killer cell receptor repertoires after unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation: analyses of CD94:NKG2A and killer immunoglobulin-like receptor expression and their associations with clinical outcome.
Zhao XY; Huang XJ; Liu KY; Xu LP; Liu DH
Biol Blood Marrow Transplant; 2007 Jun; 13(6):734-44. PubMed ID: 17531784
[TBL] [Abstract][Full Text] [Related]
6. NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation.
Ruggeri L; Mancusi A; Burchielli E; Capanni M; Carotti A; Aloisi T; Aversa F; Martelli MF; Velardi A
Blood Cells Mol Dis; 2008; 40(1):84-90. PubMed ID: 17964828
[TBL] [Abstract][Full Text] [Related]
7. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
8. Human NK cells: from HLA class I-specific killer Ig-like receptors to the therapy of acute leukemias.
Moretta A; Locatelli F; Moretta L
Immunol Rev; 2008 Aug; 224():58-69. PubMed ID: 18759920
[TBL] [Abstract][Full Text] [Related]
9. Natural killer cells as a therapeutic tool in mismatched transplantation.
Ruggeri L; Capanni M; Mancusi A; Aversa F; Martelli MF; Velardi A
Best Pract Res Clin Haematol; 2004 Sep; 17(3):427-38. PubMed ID: 15498714
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic hematopoietic stem cell transplant using mismatched/haploidentical donors.
Koh LP; Rizzieri DA; Chao NJ
Biol Blood Marrow Transplant; 2007 Nov; 13(11):1249-67. PubMed ID: 17950913
[TBL] [Abstract][Full Text] [Related]
11. Natural killer cell recognition of missing self and haploidentical hematopoietic transplantation.
Ruggeri L; Mancusi A; Burchielli E; Perruccio K; Aversa F; Martelli MF; Velardi A
Semin Cancer Biol; 2006 Oct; 16(5):404-11. PubMed ID: 16916611
[TBL] [Abstract][Full Text] [Related]
12. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation.
Passweg JR; Tichelli A; Meyer-Monard S; Heim D; Stern M; Kühne T; Favre G; Gratwohl A
Leukemia; 2004 Nov; 18(11):1835-8. PubMed ID: 15457184
[TBL] [Abstract][Full Text] [Related]
13. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
Strober S
Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
[TBL] [Abstract][Full Text] [Related]
14. Human natural killer cells in health and disease.
Shereck E; Satwani P; Morris E; Cairo MS
Pediatr Blood Cancer; 2007 Oct; 49(5):615-23. PubMed ID: 17265453
[TBL] [Abstract][Full Text] [Related]
15. Natural killer cell-based immunotherapeutic strategies.
Klingemann HG
Cytotherapy; 2005; 7(1):16-22. PubMed ID: 16040380
[TBL] [Abstract][Full Text] [Related]
16. Alloreactive natural killer cells in targeting high-risk leukaemias.
Moretta L; Locatelli F; Moretta A
Ann Rheum Dis; 2008 Dec; 67 Suppl 3():iii39-43. PubMed ID: 19022812
[TBL] [Abstract][Full Text] [Related]
17. IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation.
Koehl U; Sörensen J; Esser R; Zimmermann S; Grüttner HP; Tonn T; Seidl C; Seifried E; Klingebiel T; Schwabe D
Blood Cells Mol Dis; 2004; 33(3):261-6. PubMed ID: 15528141
[TBL] [Abstract][Full Text] [Related]
18. Haploidentical hemopoietic stem cell transplantation for the treatment of high-risk leukemias: how NK cells make the difference.
Locatelli F; Pende D; Maccario R; Mingari MC; Moretta A; Moretta L
Clin Immunol; 2009 Nov; 133(2):171-8. PubMed ID: 19481979
[TBL] [Abstract][Full Text] [Related]
19. Donor KIR3DL1/3DS1 gene and recipient Bw4 KIR ligand as prognostic markers for outcome in unrelated hematopoietic stem cell transplantation.
Gagne K; Busson M; Bignon JD; Balère-Appert ML; Loiseau P; Dormoy A; Dubois V; Perrier P; Jollet I; Bois M; Masson D; Moine A; Absi L; Blaise D; Charron D; Raffoux C;
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1366-75. PubMed ID: 19822295
[TBL] [Abstract][Full Text] [Related]
20. Rapid immune reconstitution after a reduced-intensity conditioning regimen and a CD3-depleted haploidentical stem cell graft for paediatric refractory haematological malignancies.
Chen X; Hale GA; Barfield R; Benaim E; Leung WH; Knowles J; Horwitz EM; Woodard P; Kasow K; Yusuf U; Behm FG; Hayden RT; Shurtleff SA; Turner V; Srivastava DK; Handgretinger R
Br J Haematol; 2006 Nov; 135(4):524-32. PubMed ID: 17010105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
